Background: Psilocybin-assisted psychotherapy (PAP) may be an effective intervention for a range of mental disorders. However, there appears to be a relative lack of qualitative evidence to complement emerging quantitative findings. To our knowledge, no reviews have systematically mapped the literature on qualitative studies on PAP for the treatment of mental disorders with the intent to...
Abstract Background and aims Psychedelic-assisted therapies (PAT) have emerged as promising treatments for mental health conditions such as depression, anxiety, and trauma-related disorders. However, the underrepresentation of Black, Indigenous, and People of Color (BIPOC) in PAT research and clinical practice limits equitable access and the generalizability of outcomes. This study explored the...
New treatment options are needed to improve outcomes for patients with both opioid use disorder (OUD) and injection-related infections. Psychedelic-assisted therapy (PAT) has been suggested as a potential treatment for substance use disorders (SUD). To address this need, a qualitative study was conducted to understand the attitudes toward PAT from individuals with OUD who have survived...
Psychospiritual distress (PSD) causes profound suffering in people with serious illness, yet treatment options are few and evidence of their efficacy is modest. Although high-level evidence is limited, decades of preliminary research suggest that psychedelic-assisted psychotherapy (PAP), including ketamine-assisted psychotherapy (KAP), may alleviate the anxiety, depression, and existential...
Approximately 15% of pregnant women experience postpartum depression (PPD). Even with currently available antidepressant treatments, many women will continue to be impaired by symptoms. Psychedelic therapy offers a promising transdiagnostic therapeutic strategy for several mental health disorders, and early results from current trials suggest that serotonergic psychedelics may represent a...
Background: Psychedelic therapies are gaining attention as tools to alleviate anxiety and depression across various clinical populations. However, the mechanisms behind psychedelics' therapeutic efficacy and the potential differences in how patients with certain diagnoses experience their subjective effects remain unknown. One commonly suggested mediator of positive outcomes across psychedelics...
IMPORTANCE: As psychedelic-assisted therapies gain clinical legitimacy, their cultural portability remains underexamined. While promising results have emerged from trials on existential distress in life-limiting illness, most protocols reflect Euro-American values. The expansion of these therapies calls for a pivot toward cultural humility and renewed attention to what constitutes a "good...
Applies the Void Framework to psychedelic-assisted therapy. Unique feature: the therapy deliberately induces temporary dissolution of the ego boundary — a controlled void state used therapeutically. The void is the mechanism, not the harm. Oregon and MAPS protocols as constraint implementations.
Emerging evidence supports 5-MeO-DMT as a promising, ultra-short-acting psychedelic for treatment-resistant depression and other psychiatric conditions, warranting larger RCTs.
psilocybin-assisted psychotherapy is a compelling therapeutic option warranting further investigation through rigorous, interdisciplinary research to promote an anthropologically/ethically grounded implementation in palliative settings, even beyond the oncology field.